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The brain is a sexually dimorphic organ that implies different functions and structures depending on sex. Current pharmacological
approaches against different neurological diseases act distinctly in male and female brains. In all neurodegenerative diseases,
including Alzheimer’s disease (AD), sex-related outcomes regarding pathogenesis, prevalence, and response to treatments
indicate that sex differences are important for precise diagnosis and therapeutic strategy. Pathogenesis of AD includes vascular
dementia, and in most cases, this is accompanied by metabolic complications with similar features as those assembled in
diabetes. This review discusses how AD-associated dementia and diabetes affect cognition in relation to sex difference, as both
diseases share similar pathological mechanisms. We highlight potential protective strategies to mitigate amyloid-beta (Aβ)
pathogenesis, emphasizing how these drugs act in the male and female brains.
1. Introduction
Alzheimer’s disease (AD) is the most common dementia-
related disorder, which has shown an alarming rise in its
prevalence around the world, and its number is expected to
rise over a hundred million by 2050 [1, 2]. Emerging evidence
indicates that the pathogenesis of AD is attributable to
chronic vascular pathologies [3]. Thus, ADmay be considered
a vascular disorder with neurodegenerative consequences
rather than being a neurodegenerative disorder. Biochemi-
cally, AD is characterized by amyloid-beta (Aβ) plaque
formation and tau protein hyperphosphorylation inside neu-
rons [4, 5]. The dominant hypothesis regarding AD (i.e., the
amyloid cascade hypothesis) suggests that increased accumu-
lation of Aβ peptide in the brain parenchyma leads to mem-
ory loss and cognitive decline that are clinical characteristics
of the disease [6]. The conventional hypothesis is that AD
precedes vascular dysfunction. Elevated cytokine expression
and microglial activation are also contributors to neuroin-
flammatory changes in AD [7]. Clinically, the disease
worsens by memory impairment and a decline in cognitive
ability, leading to eventual death [8]. Effective therapies for
AD have not yielded significant outcomes so far. However,
the social and economic cost of caring for AD patients makes
it rational to continue searching for effective therapies.
Important key factors that play critical roles in AD
pathogenesis include aging and decreased cerebral perfusion.
With advancing age, cerebral blood flow decreases to lower
the brain perfusion, thus placing vulnerable neurons in a
state of high energy demand, consequently leading to a cas-
cade of neuronal metabolic turmoil. A culmination of these
two factors leads to the critically attained threshold of cere-
bral hypoperfusion. Cerebral hypoperfusion is a type of
hemodynamic microcirculatory insufficiency, which can
destabilize neurons, synapses, neurotransmission, and cogni-
tive functions. These alterations can create a neurodegenera-
tive condition with senile plaque formation, neurofibrillary
tangles (NFTs), and amyloid angiopathy, leading to cognitive
impairment [9, 10]. This alternative theory of AD pathogen-
esis has been supported by experimental studies, in which the
blood-brain barrier (BBB) dysfunctions and impaired cere-
bral blood flow (CBF) have been observed [11].
Recent research findings indicate that pathological
cerebral angiogenesis may occur due to Aβ accumulation,
resulting in BBB dysfunction in AD. The abnormal increase
of Aβ concentration in blood circulation leads to decreased
nitric oxide (NO) and vascular sensitivity to endothelium-
dependent vasodilatation. This phenomenon can lead to con-
striction of blood vessels and ischemia in neighboring tissues
[12]. Also, the increase of Aβ leads to cell death and
decreased maximum vasodilator response of cerebral vessels
in the context of AD [13].
Epidemiologic studies confirmed that genetic factors play
an important role in the progression of early-onset AD
(EOAD) and late-onset AD (LOAD). The mutations in amy-
loid precursor protein (APP), presenilin-1 (PSEN1), and
presenilin-2 (PSEN2) are inherited in a Mendelian fashion,
directly causing the EOAD, while genome-wide association
studies (GWAS) have discovered many vulnerable genes
influencing the susceptibility to LOAD [14]. AD-associated
mutations in these three genes (i.e., APP, PSEN1, and PSEN2)
show high penetrance (i.e., more than 85%), are generally
autosomal dominantly inherited, and inevitably cause Aβ
aggregation and EOAD (Figure 1).
On the other hand, LOAD-developing genes inherited in
a non-Mendelian fashion raise the disease risk. First-degree
relatives of patients with LOAD have two times predictable
existence risk without an AD-affected first-degree relative.
Additionally, LOAD appears to be more frequent in monozy-
gotic than in dizygotic cotwins, which shows a major genetic
contribution in the development of the disease [15]. The
identification of the ε4 allele of apolipoprotein E (APOE ε4)
is a well-established genetic risk factor for both EOAD and
LOAD [16], which has unfolded new findings of at least 21
extra genetic risk loci for the genetically complex form of
AD, emerging from GWAS and massively parallel resequen-
cing efforts. These advances in AD genetics are positioned in
light of the current endeavor directed towards translational
research and personalized treatment of AD.
Even though genetic factors are inherited and fixed, other
nongenetic factors contribute to the ailments. These factors
include occupational exposures (i.e., pesticide spray, expo-
sure to electromagnetic fields, volatile anesthetics, and
organic solvents), lifestyle factors (i.e., alcohol consumption,
smoking, drinking coffee, body mass index, cognitive activity,
and physical activity), and preexisting diseases (i.e., trau-
matic brain injury, depression, hypertension, cerebrovascular
disease, diabetes, dyslipidemia, and cancer) [17]. Copper ion
can cause extended conformation of Aβ-peptides, which are
correlated to AD [18]. Similarly, high levels of metals like
2 Oxidative Medicine and Cellular Longevity
aluminum (Al), zinc (Zn), and iron (Fe) in the brain can also
lead to the generation of AD [19]. Lead can be absorbed by
lung epithelial cells and the gastrointestinal tract upon bind-
ing to heme groups in the blood circulation. Environmental
factors or insults such as environmental toxins, heat, starva-
tion, psychological stress, hypothermia, glucose hypometa-
bolism, anesthesia, brain trauma, and injury can stimulate
hyperphosphorylation of tau protein, Aβ aggregation, and
oligomerization, which are closely related to LOAD progres-
sion [20].
Diabetes mellitus (DM) is a complicated disorder that
affects all tissues and organs, with metabolic complications
reaching faraway to impaired glucose metabolism [21]. Type
1 diabetes mellitus (T1DM) is an autoimmune disorder,
where the insulin-producing pancreatic β-cells are destroyed,
preventing the body from producing a sufficient level of insu-
lin hormone to control normal blood glucose levels. T1DM is
mainly diagnosed in children and referred to as juvenile
diabetes, which can develop at any age [22], while Type 2 dia-
betes mellitus (T2DM) is thought to occur in its earliest
phase, from the declining sensitivity of peripheral tissues to
circulating insulin. It may lead to impaired glucose tolerance
(ITG), the proportional inadequacy of insulin, and compen-
satory hyperinsulinemia to manage glucose homeostasis [23].
The number of diabetic patients with cognitive impair-
ment has been continuously increasing. Numerous epidemi-
ological studies have linked DM with the occurrence of AD.
Insulin resistance has been proposed as the mechanism by
which DM increases AD-associated pathology [24–27]. The
global economic burden of AD-dementia care and cure is
enormous. Hence, there is an immediate need for sex-based
studies to assess AD-associated dementia and therapeutic
strategies [28–30]. This is an important consideration, espe-
cially in DM. In the present review, we outline the link
between DM and AD and dissect sex-dependent common
features on cognition between these two pathologies.
2. Sex Differences in Cognition for AD Patients
Sex differences regarding AD incidence are less clear. A Phil-
adelphia Neurodevelopment Cohort study based on brain
imaging between 8 and 22 years has explained developmental
sex differences [31]. Previous literature has highlighted some
scenarios that could affect AD dementia based on sex differ-
ences. These scenarios include (a) risk factors with the same
frequency for both genders that have a more significant effect
on one sex or another, such as APOE genotype as well as
other genetic variants located on autosomal chromosomes;
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Figure 1: Genetic and environmental factors causing Alzheimer’s disease.
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(b) risk factors with the same effect in both genders but with
different frequencies, e.g., historically, males smoke more fre-
quently, and females have less access to education; (c) risk
factors with different frequencies and effects based on gender,
e.g., males are more likely to have head traumas, while
females are more prone to head injury’s adverse events; and
(d) risk factors that are limited to one sex, e.g., prostate can-
cer and androgen deprivation therapy in men as well as preg-
nancy and oophorectomy in women [32].
Evidence from many countries documented a higher
incidence rate of AD dementia in old-aged women than
men [33, 34]. This is supported by estimates, which indicate
that almost two-thirds of patients diagnosed with AD are
women. A recent meta-analysis among Asians, Europeans,
and Americans has shown that women are at greater risk of
developing AD-associated dementia than men [35]. There
is a vague explanation for this difference, but it is assumed
that the greater percentage of women among AD patients is
due to their longer lifespan than the opposite sex [33]. Other
studies conducted in Asian [36, 37] and European [38–41]
populations showed similar trends. However, this estimate
is not well supported across all the world regions. In the
United States, numerous studies did not find sex-based differ-
ences in AD development [42–47]. Another recent study con-
ducted by the Mayo Clinic showed that the rate of progression
of mild cognitive impairment (MCI) to AD is identical in both
sexes in the age group of 70-79 years, but it also reported cases
of AD progression in women older than 80 years [48, 49].
Contrary to these findings, a recent report documented a
higher incidence rate of AD dementia in men. Moreover, they
mentioned a decline in dementia incidence in men (0.6; 95%
CI: 0.4–0.9) but not in women (1.0; 95% CI: 0.7–1.3) [50].
Also, the Cache County Study (USA) reported a higher AD
occurrence in men than women up to age 78. However, older
subjects exhibited a reverse trend [51].
Until now, no exact reasons are established for the above-
mentioned discrepancy. However, time and geographic
region may affect the incidence of AD dementia [52, 53]. In
a recent longitudinal population-based study, neuropathic
abnormalities were more common in white women, but
microinfarcts were more common in Japanese-American
men [54]. There may be variations in sample, size, and age
distribution in addition to social, cultural, and historical fac-
tors in sex-based results in Asian, European, and American
studies. Inflammation can be another cause of dementia in
AD, where different effects have been observed in males
and females. Inflammatory dysregulation is also found to be
more prominent in females [55, 56]. There is a significant
sex difference in microglia during development, which is a
primary immune cell in the central nervous system. During
the adolescent period, women have more microglia than
men, when women-linked disorders such as depression and
anxiety tend to rise. There is a possibility that disturbance
in microglia at this developmental stage leads to neurodegen-
erative disorders in later stage of adulthood [55–57]. Low-
grade inflammation is a risk factor for several medical impli-
cations like T2DM, obesity, anxiety, and depression. All such
risk factors develop AD and other types of dementia in
humans [58]. Thus, comprehensive global studies to assess
the risk factors for AD dementia among both men and
women are warranted to understand these differences.
3. Sex Hormones and Risk of AD
The fully grown brain structure and its development, as well
as the brain activities and biochemistry, vary among genders
[59]. Sex-determining genes and fetal hormonal program-
ming trigger such differences in both male and female brains.
These types of differences have imperative implications for
brain-based disease risk and clinical and investigational
approaches. Altmann et al. [60] documented that women
who are positive for APOE ε4 have a higher risk of having
AD than men who are positive for this allele since they show
more prevalent behavioral disinhibition [61].
Some studies have unveiled that men with AD have
different levels of sex hormones than normal men. Hence,
male sex hormones have been hypothesized as AD-
developing risk factors through immunomodulatory effects
on known inflammatory AD risk factors, such as tumor
necrosis factor-alpha (TNF-α) [62]. Barron and Pike [63]
have demonstrated that age-related depletion of estrogen
hormone in women and testosterone in men establishes risk
factors for AD development. Generally, sex steroid hormones
have anti-inflammatory activities, which may have interac-
tions with many other AD-developing agents (Figure 2).
Progesterone plays an essential role in females during the
childbearing period, but after menopause, there is a rapid
decline in ovarian sex hormones such as 17 beta-estradiol
and progesterone. Before menopause, oophorectomy leads
to a significant loss of estrogen, progesterone, and testoster-
one, disrupting the hypothalamic-pituitary axis [64]. There
is a reduction of male sex hormones with increasing age,
but its impact is not as severe as in female sex hormones
(e.g., progesterone and estrogen).
Several animal and cellular studies have proven the neu-
roprotective effect of estrogenic compounds [65–76]. Studies
on various animal and cellular models have shown enhanced
synapse formation on hippocampal dendritic spines, main-
taining hippocampal function while aging [77–80]. When
estrogen is high, there is also increased CBF and glucose
metabolism [81]. Indeed, an increase in choline acetyltrans-
ferase (ChAT) activity in the basal forebrain and hippocam-
pus is also observed. For instance, ChAT is responsible for
acetylcholine (ACh) synthesis, a neurotransmitter whose
level is reduced in AD. Increased ChAT activity reduces the
aggregation of Aβ neurotoxicity associated with AD [82, 83].
Although estrogen effects on animal and cellular models
are quite beneficial, the impact of reduced estrogen levels
due to menopause, oophorectomy, and hormone replace-
ment therapy (HRT) on the risk of AD in women remains
controversial. Previous literature reported a reduced risk of
AD in women who start HRT within a short period after nat-
ural menopause or after oophorectomy [84, 85]. In a cohort
study conducted on oophorectomy and aging by the Mayo
Clinic, an increased risk (i.e., almost double) of dementia
was reported in women who underwent bilateral oophorec-
tomy before menopause [85, 86]. Contrary to it, in women
who started HRT just after bilateral oophorectomy and
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continued with HRT therapy up to the age of natural meno-
pause, there was no risk of developing AD [87].
Contradicting estrogen’s beneficial effect, the Women’s
Health Initiative Memory Study (WHIMS) has shown a
reverse effect [88]. In this large randomized clinical trial
study of HRT, there was a twofold increase in the risk of
dementia among women over 65 years of age. The observa-
tional finding could be the result of confounding, which
differs from the clinical trial results. Generally, women who
use HRT therapy belong to a higher socioeconomic class
having a higher education level who can afford better health
services. This may be the reason for the lower risk of AD in
those women. Another factor could be the timing of HRT
therapy [89].
It was proven by observational studies that if initiation of
HRT is done around the time when menopause starts (i.e.,
not too late before menopause), there is a reduced chance
of developing AD. Women who started HRT within five
years of menopause had a 30% less chance of getting AD as
compared to women who never used HRT. However, after
five years of menopause, delayed HRT therapy had reverse
effects, which did not result in reduced AD risk. On the con-
trary, they have a double risk of suffering AD, particularly
when they started after menopausal age [90].
Other studies, such as the Multi-Institutional Research
on Alzheimer Genetic Epidemiology (MIRAGE) and North-
ern California Kaiser Permanent, also reported a beneficial
HRT effect. It starts around menopause with a reduced risk
of developing AD, while delayed treatment has reported
inverse results with more chances of dementia [87, 91]. The
WHIMS trial results were also on a similar track since, in
their study, women aged between 65 and 79 years were taken
as subjects, and therapy was initiated 10-20 years after
menopause.
Currently, two hypotheses are supporting the timely ini-
tiation of HRT in women around menopause. The first
hypothesis is a window of opportunities. According to this
hypothesis, long-term estrogen depletion (LTED) can dimin-
ish estrogen receptor-alpha (ERα) in the CA1 regions of the
hippocampus, which is highly sensitive to estrogen therapy,
increasing cognition and neuroprotection [92]. Therefore,
estrogen initiation after LTED, when ERα receptors are
already downregulated, does not result in estrogen’s neuro-
protective benefit. The other hypothesis is the healthy cell
bias of estrogen benefit. It assures that estrogen-only therapy
shows its neuroprotective benefit when applied to the healthy
neuron, and no beneficial effect was observed on neurons
with mitochondrial damage [93].
4. AD-Associated Dementia and DM
Perturbed cerebral glucose metabolism, an invariant patho-
physiological feature of AD, may play a critical contributor
to the pathogenesis of DM [94]. The brain’s high energy
demand is primarily completed from glucose metabolism,
making it vulnerable to impaired energy metabolism. Hence,
defective glucose homeostasis heavily affects the brain’s cog-
nitive functions, where observations have been documented
by many clinical and experimental studies [95]. Substantial
research evidence has also shown that in aging animals,
performance deficits on a series of cognitive tasks occur due
to insufficient cerebral glucose supply, which could be
reversed by increasing glucose availability in selective brain
areas of aging animals. Microinjection of glucose into the
medial septum, hippocampus, striatum, and amygdala can
enhance memory processing. These findings indicate that
an aging individual is at a greater risk of developing AD
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Figure 2: Sex differences with Alzheimer’s disease and diabetes.
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due to exposure to glucose deprivation, especially during a
highly prolonged cognitive task or training.
Biomarkers may expose the occurrence and severity of
hyperglycemia (i.e., diabetes itself) and diabetic vascular
complications. In the blood, hemoglobin A1c (HbA1c) may
be considered as a biomarker for the presence and severity
of hyperglycemia, implying diabetes or prediabetes, or, over
time, as a biomarker for a risk factor(i.e., hyperglycemia as
a risk factor for diabetic retinopathy, nephropathy, and other
vascular diabetic complications) [96].
5. Sex Differences in DM
Sex-related changes in lifestyle may cause differences in the
risk of developing DM and differences in this disease’s occur-
rence in men and women [97]. A classic example of sex-
gender differences is idiopathic diabetes, which accounts for
75% of males’ dominance [98]. Remarkably, male predomi-
nance starts after adolescence. It is noteworthy that T1DM
is characterized by the male : female ratio of 1 : 1 with a slight
male predominance [99]. It is expected that around three
hundred sixty-six million people will suffer from T2DM
worldwide by 2030. Despite the efforts to control it, the num-
ber of patients will rise from the current 2.8% to 4.4% of the
total human population [100]. The prevalence of T2DM is
10% more in women than in men, similar to the number of
women with impaired glucose tolerance, which is 20% more
than that of men [101]. The middle-aged population is
more affected, surpassing half of the total diabetic subjects,
with diabetes occurrence increasing with aging male and
female subjects; the highest rates were recorded in older
women [102].
It is assumed that sex differences play an imperative role
in the pathogenesis of diabetes. Increasing imbalances in sex
hormones (such as high progesterone levels in females or tes-
tosterone in males) is linked with insulin resistance (IR). Due
to the production loss of the endogenous ovarian hormone,
women are at higher risk of developing visceral obesity after
menopause. Besides, IR triggered oversecretion of the andro-
gen hormone, leading to menstrual disorder in overweight
young women. In Japan, for gestational diabetes, diagnostic
criteria were revised to properly manage glucose intolerance
during pregnancy. Even though glucose intolerance during
pregnancy returns to normal after delivery, gestational dia-
betic patients should be checked regularly for the early detec-
tion of T2DM. Besides, practices and behaviors are associated
with lifestyles that include nutritional intake and workout,
consequently making gender-specific drugs more critical in
curing DM [103].
T2DM is more commonly diagnosed with age and body
mass index (BMI). However, obesity is a considerable risk
factor for DM, which is more common in females. Significant
differences in the sex ratio are observed across various coun-
tries. Striking sex and territorial disparities in the escalation
of obesity-related T2DM predominance progressed in the
last 30 years, showing a characteristic relationship between
dissimilarities in lifestyle, culture, migration, ethnicity,
socioeconomic status (SES), social involvement, and gene-
environment interactions [104] (Figure 3).
These diversities make differences between males and
females in predisposition, development, and clinical presen-
tations. Some more factors, making complications and risks
differently in both sexes, are genetic factors, sedentary life-
style, and epigenetic mechanisms. Lifestyle, environment,
and genetic background make a more pandemic increase in
T2DM and its related problems.
In T2DM, sex and gender disparities are equally impor-
tant in its development, presentation, diagnosis, awareness,
treatment, and prevention [97, 105]. Females are risk-free
up to a broader level of BMI because they accumulate lipids
in subcutaneous adipose tissues (SAT), which stimulate less
harm than that in visceral adipose tissue (VAT), which takes
place in the male [106]. Low levels of testosterone in men are
linked with IR and abdominal obesity or central obesity,
which are a significant contributor to the development of
T2DM in men [107]. DM shows a decrease in the more
accommodating favorable group of women’s risk factors
compared to those of men, causing more considerable differ-
ences in abdominal adiposity, where risk factors are associ-
ated with coagulation and inflammation, involving DM in
normal females than in males [97]. It was observed in a study
on Swedish DM patients that male diabetic subjects who were
more than 60 years old have extra supportive control of blood
pressure (BP) and high blood glucose (hyperglycemia) in
comparison to female diabetic subjects, regardless of almost
the same medicine given to both sexes. Angiotensin-
converting enzyme (ACE) inhibitor was given more fre-
quently to male patients [108].
Another finding suggested that weight reduction of
more than three percent of body weight produced a higher
decline in DM risk factors in males than in females. Despite
the promising effects of intensive lifestyle modification
(ILS) in males, baseline risk factors were more abundant
in them, likely obscuring any sex differences in incident
DM [109]. Pound et al. [110] found that poor diabetic con-
trol was noticed in females compared to that in males at all
ages from 15 to 17 years (mid teens) onwards. The argu-
ment is that it may be due to women’s responsibilities with
the care of their family and with the management of their
DM.
Recently, a study was conducted on German patients to
analyze sex differences with adherence and inadequate glyce-
mic control in a group of T2DM subjects. The research out-
come exhibited considerable gender-specific dissimilarities
with the involvement of adherence and inadequate glycemic
control. In males and females, poor glycemic control was
noticed in 37% and 19% of the nonadherent participants
and in 19% and 18% of the adherent participants [111].
The study of Yoshimura et al. [112] on T2DM in the
Japanese population demonstrated that higher energy utiliza-
tion of each 1000 grams of average body mass is equivalent to
the augmentation of the body mass index in males, but not in
females. Consumption of soft drinks by men and women and
consumption of alcohol, particularly in women, have been
correlated with the body mass index’s augmentation. From
the perception of nutritional intake, these findings specifi-
cally indicate that gender differences exist in the pathogenesis
of obesity in aged T2DM individuals [112].
6 Oxidative Medicine and Cellular Longevity
Regarding the gestational DM, pregnant women with
male fetuses have lesser beta cell activity and higher post-
prandial glycemic response than pregnant women carrying
female fetuses. However, the male fetus is independently
linked with increased chances of gestational DM in the
mother. It can be concluded that fetal sex is already an
unknown factor pertinent to maternal glucose homeostasis
in pregnancy [113]. Siddiqui et al. [114] reviewed that male
diabetic patients live more effectively with DM by displaying
lesser dismay, by having worries but remaining lively, and by
keeping a positive attitude. They manage their illness more
optimistically and undergo minor social stresses. Sex differ-
ences become more important when one must accept to sur-
vive effectively with diabetes. Diabetic women wish to build
up a positive attitude towards the disease and its manage-
ment [114].
An examination of the types and treatments of DM high-
lights three key factors such as (a) it is a long-lasting and
mentally and interactively challenging disease, (b) it is
impossible to get rid of this disease, and (c) diabetes may be
managed but cannot be cured. Diabetic individuals must
learn to survive with this problem [114].
More studies are needed to unveil the process of how
T2DM is pathophysiology linked with sex-dimorphic and
diabetes-related problems that could help to discover ways
for a more personalized care in the future and to encourage
further awareness regarding sex and gender-specific risk
factors.
6. Pathophysiological Mechanisms of AD
and T2DM
In the case of both AD and T2DM, it has been found that
there was a noticeable impairment of energy and glucose
metabolism, which has been revealed by magnetic resonance
imaging (MRI) and positron emission tomographic (PET)
studies [27]. In both these diseases, amyloid genesis remains
a principal feature. Similarly, in the pancreatic islets of Lan-
gerhans in T2DM patients, islet amyloid polypeptide (IAPP)
deposits were identified [115]. Intriguingly, fibrils and oligo-
mers with more severe diabetic traits similar to AD mouse
models that overexpress APP have been developed from
diabetic mice overexpressing IAPP [116]. Under conditions
of oxidative stress and endoplasmic reticulum stress,
advanced glycation end products (AGEs) and their receptors
(RAGE) are gathered in the sites of diabetic complications,
including atherosclerotic plaques, retina, and kidney [117].
Likewise, tau and glycated products of Aβ form in transgenic
AD models and postmortem brains of AD individuals under
similar conditions of stress forming a vital component of
NFTs [118]. Additionally, in T2DM and AD cases, there were
numerous mutual pathophysiological features [119], as
shown in Figure 4.
6.1. Inflammation. In T2DM, IR is regarded as an essential
feature, often accompanied by inflammation, especially with
raised levels of the inflammatory mediators like α-1-antic-
hymotrypsin, C-reactive protein (CRP), and interleukin-6
(IL-6). Furthermore, it is hypothesized that raised levels of
products of the acute-phase reaction in inflammation are
associated with immunological dysfunction, leading to IR.
Similarly, there is proof that inflammatory processes are
related to AD [120, 121]. On the other hand, in AD
patients, inflammatory products gather at different rates
compared to healthy control subjects. Moreover, in AD
patients, IL-6 is present in senile plaques [122], and raised
immunoreactivity to IL-6 is noticed in ventricular and lum-
bar cerebrospinal fluid.
Few studies have associated CRP with a raised risk of AD


































































Figure 3: Progression of type 2 diabetes mellitus with social and biological conditions.
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there is a reduced incidence of AD in individuals who are
prescribed nonsteroidal anti-inflammatory drugs (NSAIDs)
to treat chronic pain [125, 126]. Remarkably, peroxisome
proliferator-activated receptor-γ (PPARγ) agonists have
been found to have anti-inflammatory effects [127].
6.2. Mitochondria and Oxidative Stress. In the pathogenesis
of both T2DM and AD, oxidative stress and mitochondrial
dysfunction have a crucial contribution, signifying a possible
association [128]. It has also been observed that, in T2DM,
there is a raised level of oxidative stress along with a lower
level of antioxidant capacity [128], which suggests that this
can ultimately lead to neuronal injury with mitochondria as
specific targets [129]. Conversely, when studied in a rat
model of T2DM, it has been found that brain mitochondria
exhibit age-related weakening of the respiratory chain and
uncoupling of oxidative phosphorylation [130], which is
essential for the production of adenosine triphosphate
(ATP).
Because the mitochondria provide approximately 90% of
the ATP required for normal neural functions, mitochondrial
dysfunction can cause loss of metabolic control and neural
degeneration. Since the brain is profoundly reliant on ATP
production, it is more vulnerable [131]. Besides, as per the
mitochondrial cascade hypothesis, the rate of mitochondrial
damage accumulation is determined through the basal rate
of production of reactive oxygen species (ROS) by the elec-
tron transport chain, which in turn is determined by genetics.
Thus, oxidative changes in mitochondrial proteins, lipids,
and nucleic acids increase ROS production and stimulate
the cells towards Aβ production, NFTs formation, and tau
phosphorylation [132].
6.3. Advanced Glycation End Products. Advanced glycation
end products (AGEs) are produced when reducing sugars
do not enzymatically react with the amino groups of proteins
and then go through further reactions (including condensa-
tion, dehydration, and rearrangement) to turn into irreversibly
cross-linked heterogeneous derivatives [133]. Interestingly, in
1912, AGEs were initially identified as Maillard reaction’s
end products [134]. Although AGEs can build up in several
cells because of normal aging, the accumulation rate is mark-
edly increased in DM [135].
Interestingly, in AD, the formation of an elevated level of
AGEs is also noticed. Nonetheless, in AD, extracellular accu-
mulation of AGEs is more likely to be produced by the
enhanced oxidation of glycated proteins, such as redox-
active iron bound to proteins in amyloid plaques [136].
Alternatively, in both DM and AD, intracellular accumula-
tion of AGEs is generated through the presence of phos-
phates and reactive sugars, for instance, fructose. The
metabolic consequences include hypometabolism of glucose,
impaired cell function, and oxidative stress [137]. AGEs have
also been observed in the central nervous system of diabetic
patients, which could offer a mechanistic connection [96].
6.4. Obesity and Metabolic Syndrome. Obesity, particularly
central body obesity, is regarded as an independent risk fac-
tor for metabolic syndrome, a disorder of hypertension, IR,
and dyslipidemia. Furthermore, for the development of
T2DM, metabolic syndrome and obesity are vital risk factors






























Figure 4: The outline of pathogenic mechanisms by which type 2 diabetes mellitus can cause Alzheimer’s disease pathogenesis.
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[138, 139]. The evidence found in the following studies indi-
cates that there might be a connection with AD as well. In the
Baltimore Longitudinal Study of Aging, a raised AD occur-
rence rate was reported among females with a BMI greater
than 30 and males between 30 and 45 years old with weight
gain [140, 141].
Similarly, another study found that males and females
with a midlife BMI greater than 30 have an increased risk
for AD [142]. On the other hand, a Swedish study found that
with every 1.0 increase in body mass index at the age of 70,
the risk of AD increased by thirty-six percent [143]. In
another study, it was found that individuals with AD have a
considerably lower mean plasma concentration of high-
density lipoprotein cholesterol, higher mean plasma concen-
tration of glucose and triglycerides, and larger mean waist
circumference [144]. In terms of the regulation of brain func-
tions, a significant contribution of leptin may also be present.
In recent times, it has been recommended by Han and Li
[145] that research on the suggested connection between
AD and T2DM would progress by studying the faulty sig-
naling of leptin in connection with the lack of a disturbed
signaling of insulin [145].
6.5. Autophagic Impairments in AD and T2DM. In most neu-
rodegenerative diseases, the intracellular buildup of mis-
folded protein aggregates is a significant characteristic
[146]. The aforesaid protein aggregates are found to be
cleared from the neurons by the process called autophagy.
Autophagy is also significant for the maintenance of neuro-
nal homeostasis [147, 148]. As neurons age, they accrue
harmful intracellular protein aggregates and damaged organ-
elles, including mitochondria, that must be straightaway
cleared for the neurons’ proper functioning at a physiological
level [149].
Recently, experiments have revealed that autophagic
machinery controls the normal function of pancreatic β-
cells, and it is also associated with the T2DM pathophysiol-
ogy. IR leads to the generation of oxidative stress on
insulin-responsive tissues. In the previously mentioned cases,
an elevated level of autophagy plays a protective role [150].
Besides, except for indirect effects, some researchers describe
the direct influence of IR on autophagy by inhibiting the
mechanistic target of rapamycin (mTOR) signaling pathway
[151].
7. Mechanistic Linkage of T2DM and
AD Hallmarks
Evidence suggested that brain IR intensely stimulates the for-
mation of Aβ and tau pathologies [152–154], as stated in
Figure 5.
7.1. Aβ Pathology. It has been indicated by growing research
that hyperinsulinemia may confer the risk of AD by regulat-
ing the toxicity of Aβ. The insulin-degrading enzyme is
responsible for the degradation of the Aβ protein; moreover,
it degrades insulin [116]. On the other hand, in T2DM, insu-
lin concentration, which plays a role as a competitive sub-
strate for the insulin-degrading enzyme, is increased via
peripheral hyperinsulinemia.
In contrast, peripheral hyperinsulinemia can inhibit the
Aβ degradation that progressively builds up to produce
insoluble plaques. In both glia and neurons, the insulin-
degrading enzyme has formerly been recognized as the pri-
mary Aβ regulator [155]. Interestingly, in Tg2576 AD trans-
genic mouse models, by investigating the influence of IR
induced by diet on amyloidosis, Ho et al. [156] observed that
only at six months of age do the animals exhibit the first signs
of memory deficits. The aforesaid research was consistent
with the theory that, for the detected elevated comparative
risk for neuropathology of AD, IR might play an essential
role and reveals the first proof to recommend that IR signal-
ing can affect the production of Aβ in the brain.
In people affected with T2DM, increased plasma glucose
levels are regarded as a commonly observed pathological
characteristic. A convincing association between AD and
glucose metabolism was established in a study that stated that
hyperglycemia could modulate the extracellular Aβ concen-
trations and neuronal activity in vivo. All these findings col-
lectively signify that the activation of the ATP-sensitive
potassium channel can mediate the response of hippocampal
neurons towards hyperglycemia through coupling metabo-
lism with neuronal action and brain interstitial fluid levels
of Aβ [157].
In the case of lipid metabolism, insulin has been found to
have a significant contribution. Moreover, increased free
fatty acid synthesis and elevated lipolysis are caused by the
weakening of insulin signaling [122]. In the plasma mem-
brane, the interaction among APP and cholesterol is essential
for the synthesis and clearance of Aβ, as revealed by recent
studies. Captivatingly, elevated Aβ production was exhibited






Figure 5: The role of insulin resistance in the pathogenesis of
Alzheimer’s disease.
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by the Tg2576 ADmice raised on a diet containing high cho-
lesterol and high fat [158].
7.2. Tau Pathology. A host of phosphatases and kinases
regulates a complex balance between dephosphorylation
and tau phosphorylation to preserve neuronal homeostasis
under physiological conditions [159]. While components of
the mitogen-activated protein kinase (MAPK) pathway lie
downstream of one arm, glycogen synthase kinase-3-beta
(GSK-3β) and protein kinase B (PKB or AKT) are found to
be located downstream at the other arm of the insulin signal-
ing pathway [160]. Again, AKT keeps GSK-3β inactive and
at the inhibitory serine-9 residue, which phosphorylates
GSK-3β. Through phosphorylation at the tyrosine-216 resi-
due, GSK-3β is converted to its active form under conditions
of IR.
In the AD brains, active GSK-3β causes hyperphosphor-
ylation of tau to produce pathological epitopes, namely,
PHF1, AT8, and AT100, which make up NFTs and pretan-
gles [161]. Phosphatases, particularly protein phosphatase
2A (PP2A), are found to regulate tau. Furthermore, at a phys-
iological level, PP2A can cause dephosphorylation of kinases
p70S6K and GSK-3β to preserve phosphorylation of tau
[162]. Fascinatingly, some investigators have revealed
PP2A downregulation in both T2DM and T1DM mice.
The aforesaid finding recommends that IR might exacerbate
the phosphorylation of tau via the downregulation of PP2A
[163, 164]. On the other hand, apoptosis is stimulated by dia-
betes through the caspase-3 activation in affected tissues
[165]. In a different study, Kim et al. [166] demonstrated
an elevated level of tau cleavage and phosphorylation in
db/db mice’s brains through an animal model of T2DM for
diabetic dyslipidemia.
8. Emerging Therapeutic Approaches in AD
and Diabetes
Despite the efforts to develop therapies for AD, success at the
clinical level is still unsatisfactory. Several strategies for man-
aging AD, such as immunotherapy against Aβ, antioxidants,
anti-inflammatory agents, natural products, and nutrition-
based approaches, have been tried. Presently, for the treat-
ment of mild to moderate AD, cholinesterase inhibitors
(i.e., donepezil, rivastigmine, and galantamine) are used,
whereas the N-methyl-D-aspartate (NMDA) receptor antag-
onist (i.e., memantine) is used for the treatment of severe
cases of AD [167]. The major problem with using these drugs
lies in providing symptomatic and short-term benefits only
without affecting the pathogenic mechanisms involved in
the disease [168]. Rigorous work has been done in drug dis-
covery in the last decade to develop disease-modifying drugs
to counter AD progression. Because of the slow progression
of the pathophysiological process in AD, it is necessary to
develop such drugs, which target this disease at the early pre-
symptomatic stage, when the disease is still hidden.
8.1. Insulin. Insulin, which is primarily secreted by the pan-
creas’ β-cells, regulates blood glucose levels [169]. Insulin,
through receptors located in the olfactory bulb and thalamus,
executes several brain functions, like food intake and cog-
nitive function, including memory [170]. Impairment in
regulating blood glucose levels and IR may be linked to
ACh synthesis, which is linked to the neurodegenerative
disorder in diabetes, by the ACh transferase enzyme,
which is expressed in insulin receptor-positive cortical
neurons [171]. In individuals with early MCI and AD, ver-
bal memory recall, especially in APOE4-individuals, was
facilitated due to acute intranasal administration of 40 or
20 IU of insulin. However, following administration of
insulin, memory-impaired APOE4 individuals exhibited
lesser recall, suggesting the role of the mediating effects
of insulin in CNS [172].
Further experiments with the same group have con-
firmed that three weeks of intranasal insulin enhanced func-
tional status, verbal memory, and attention in MCI and AD
individuals. This treatment has elevated plasma concentra-
tions of the short form of Aβ peptide, resulting in an
enhanced ratio of Aβ 40/42 [173]. The actions of insulin on
cognition are dose dependent (with maximal effect at
20 IU) and controlled by the genotype of APOE [174].
8.2. Insulin Secretagogues. Glimepiride binds with sulfonyl-
urea receptor SUR1, which is present on the pancreatic cell’s
membrane, and this binding can eventually induce secretion
of insulin by closing the potassium channel [175]. Glimepir-
ide is also found to have additional pancreatic actions,
including activating PPARγ, inducing the release of glycosyl-
phosphatidylinositol- (GPI-) anchored proteins, and elevat-
ing glucose uptake [176]. It has been reported that it docks
to PPARγ and shows PPARγ agonistic activity in a cell-
based transactivation assay [177]. Besides, it can upregulate
the PPARγ target gene expression, including leptin and
aP2, also increasing the interaction of PPARγ with cofactors
[178]. On the other hand, it has been revealed that the activa-
tion of PPARγ can reduce senile plaque levels and Aβ levels,
which, in turn, improve the cognitive function in AD individ-
uals [179].
8.3. Insulin Sensitizers.Metformin is most commonly used as
an orally active biguanide. It can reduce insulin resistance
through potentiating insulin action and lowering glucose
effects (i.e., by subduing gluconeogenesis in the liver). More-
over, through AMP-activated protein kinase (AMPK), met-
formin can enhance the insulin sensitivity of skeletal
muscle and liver [180]. In a study by Gupta et al. [181], the
authors stated that upon exposure to metformin, increased
insulin effects could prevent AD-related pathological and
molecular features in a cell culture model of insulin resis-
tance. On the other hand, following treatment with metfor-
min, enhanced viability of neurons was observed in an
in vitro model of ischemia [182]. Henceforth, in decreasing
neuronal cell injury and neuropathy linked with hyperglyce-
mia in diabetes, the use of metformin might be useful. In
human subjects, it was observed that treatment with metfor-
min markedly reduces the risk of dementia, as revealed by a
Taiwanese clinical study [183]. Some T2DM medications
and their impact on AD are shown in Table 1.
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8.4. Amylin Analog. Amylin is a small peptide hormone,
which is secreted along with insulin from the pancreatic β-
cells. Interestingly, amylin shares several similar features with
Aβ, including being degraded by an insulin-degrading
enzyme and having a similar β-sheet structure [184]. BBB
can also be crossed by amylin and appears to contribute to
the regulation of anxiety, mood, and memory [185]. Due to
its amyloidogenic potential, the Food and Drug Administra-
tion has approved its analog pramlintide for T1DM and
T2DM. It has been found that plasma levels of amylin are
markedly decreased in AD individuals. Reduced neuroin-
flammation, decreased oxidative stress, and improved mem-
ory might be observed due to pramlintide administration, as
revealed by preclinical results in AD mouse models [186].
Further studies are required to evaluate the potential role of
amylin and its analog in AD.
8.5. PPARγ Agonists. In AD patients’ brains, PPARγ found in
a significant amount is considered a critical neuromodulator
[187]. PPARγ contributes to many processes involved in the
pathogenesis of both AD and diabetes, including cell differen-
tiation and growth and metabolic and inflammatory processes
[188]. Originally, thiazolidinediones (i.e., pioglitazone and
rosiglitazone) were used to explore the contribution of
PPARγ. Their mechanism involves stimulation of PPARγ
activity in response to insulin alterations, thus causing a drop
in the serum glucose level [189]. In addition, these drugs pro-
mote neuronal Ca2+ homeostasis in the hippocampus [190],
improve IR [191], promote cholesterol homeostasis [192],
and decrease cerebral inflammation via inhibition of tumor
necrosis factor and interleukin-6 [193]. Such activities are pos-
tulated to improve AD patients’ cognitive function and regu-
late Aβ peptide proliferation [194]; thus, it can prevent
many dementia cases in upcoming years by controlling these
risk factors [195].
9. Conclusion and Future Perspectives
The prevalence of AD and other types of dementia across
most regions of the world is higher in women than in men,
Table 1: Type 2 diabetes medications and their impact on AD.
Classification Mechanism Examples Impact on AD References
Biguanide (insulin
sensitizers)
(i) Primarily decreases hepatic glucose production














(i) Selective PPARγ antagonist




(i) Reduces Aβ levels
(ii) Decreases cerebral glucose
utilization and increases ROS
production





(i) Interferes with alpha-glucosidase, thereby inhibiting




(i) Decreases oxidative stress
(ii) Prevents brain aging and
improves cognition






(i) Enhances insulin secretion by their interaction with










(i) Blocks ATP-dependent potassium channels









(i) Slows gastric emptying, promotes satiety, and
suppresses the abnormal postprandial rise of glucagon
Pramlintide
acetate
(i) Neuroprotective effects [186, 208]
GLP-1 analog
(i) Dose-dependent and glucose-dependent
augmentation of insulin secretion
(ii) Reduces gastric emptying time, suppresses





(i) Reduces APP and Aβ levels





(i) Prolongs active incretin levels
(ii) Increases insulin synthesis and release from
pancreatic beta cells and decreases glucagon secretion
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especially in the elderly. The sex differences in the brain begin
with sex-determining genes and fetal hormonal program-
ming. Understanding these differences can significantly
impact risk estimation, monitoring, and management of
brain disorders. A cohort study published in 2015 showed
that women who are positive for the APOE4 are more prone
to develop AD than men. Instead of pooling data for sexes,
more effort is needed to identify numerous other factors
implicated in dementia by sex, speeding up efforts to explore
new directions for personalized treatment and managing var-
ious dementia types. Regarding AD, studies indicate that
there is a more rapid progression of hippocampal atrophy
in women than in men. Nevertheless, men progress towards
AD, probably due to the severe periventricular white matter
hypersensitivities and reduced global cognitive performance.
In terms of clinical presentation, men show more aggressive
behavior, more comorbidity, and more mortality, while
women have more affective symptoms and disabilities with
longer survival time.
Besides genetic and brain-based cognitive risk factors,
social factors also affect the cause, risk, and outcome of differ-
ent dementias. Educational and occupational levels are two
major social causes, which affect both genders, and some
social stigma is associated with these factors, particularly in
the older generation. Behavioral and lifestyle factors such as
physical exercise, diet, nutrition, smoking, and alcohol abuse
affect both genders differently, thereby influencing different
dementia types, particularly vascular dementia. The number
of diabetic patients with neurological manifestations has
been continuously increasing, with many epidemiological
studies reporting an intricate linkage between diabetes and
AD occurrence. T2DM and AD share many mutual patho-
physiological features like glucose metabolism and noticeable
impairment of energy. Oxidative stress, accumulation of
intracellular AGEs, and mitochondrial dysfunction have a
crucial contribution in both these diseases, signifying a possi-
ble association. Insulin resistance and leptin signaling are
turning out to be potential target mechanisms involved in
diabetes-induced AD pathology. The global economic bur-
den of AD-dementia care and cure is enormous. Hence, there
is an immediate need for extensive sex-based studies to assess
AD-associated dementia and therapeutic strategies.
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